Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry

Key Findings:  This study was conducted to assess changes in the quality of life in patients with symptoms of autism spectrum disorder (ASD) who use cannabis-based medicinal products (CBMPs) for efficacy and safety. Results showed an overall safe and tolerable profile, and participants had improvement in quality of life, as well as anxiety and sleep symptoms following CBMP treatment. Also reported was a reduction in concomitant prescribing of benzodiazepines and neuroleptics.

Type of Study:  Meta-analysis

Study Sample Size:  74

Study Result:  Positive

Study Location(s):  United Kingdom

Year of Pub:  2022

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Cannabinoid (unspecified)

Phytocannabinoid Source:  Unspecified

Receptors Studied:  CB1

Ligands Studied:  GABA, Serotonin

Dosage: Median dose: CBD 10.0mg/day Δ 9 -THC 112.5mg/day

Route of Administration:  Inhalation, Oral (Ingestion), Sublingual/Oromucosal

Link to study